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PTreatment of Patent Foramen Ovale
ranscatheter Treatment of Atrial Septal Aneurysm
ssociated With Patent Foramen Ovale for Prevention
f Recurrent Paradoxical Embolism in High-Risk Patients
ndreas Wahl, MD,* Ulrike Krumsdorf, MD,‡ Bernhard Meier, MD,* Horst Sievert, MD,‡
tephan Ostermayer, MD,‡ Kai Billinger, MD,‡ Markus Schwerzmann, MD,* Ulf Becker, MD,*
hristian Seiler, MD,* Marcel Arnold, MD,† Heinrich P. Mattle, MD,† Stephan Windecker, MD
ern, Switzerland; and Frankfurt, Germany
OBJECTIVES This study sought to investigate the safety and efficacy of transcatheter treatment of atrial
septal aneurysm (ASA) associated with patent foramen ovale (PFO).
BACKGROUND Patients with both ASA and PFO are at high risk for recurrent paradoxical embolism.
METHODS The procedural, echocardiographic, and clinical outcomes of 141 patients with ASA  PFO
and 1 paradoxical embolic event undergoing transcatheter treatment were compared with
220 patients with PFO alone.
RESULTS Device success (ASA  PFO, 99.3%; PFO alone, 99.5%; p  0.75) and procedural
complications (ASA PFO, 0.7%; PFO alone, 3.2%; p 0.12) were similar in both groups.
Maximal atrial septal excursion in patients with ASA  PFO decreased from 16  4 mm
before to 4 3 mm after the intervention (p 0.0001). At 6 months follow-up, right-to-left
shunt was abolished in 120 (86%) patients with ASA  PFO, compared to 187 (85%)
patients with PFO alone (p  0.80). Freedom from recurrent transient ischemic attack,
stroke, and peripheral embolism at 4 years was 95% (ASA  PFO) and 94% (PFO alone, p
 0.70), respectively. A residual right-to-left shunt after the intervention was the only
predictor for recurrence (hazard ratio [HR] 6.9; 95% confidence interval [CI] 1.3 to 36.9, p
 0.03) in patients with ASA  PFO.
CONCLUSIONS Transcatheter treatment of ASA  PFO is safe and effective in patients with paradoxical
embolism. The procedure effectively abolishes right-to-left shunt and decreases atrial septal
mobility. Long-term prevention of recurrent events appears favorable when compared to
patients with PFO alone. (J Am Coll Cardiol 2005;45:377–80) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.043College of Cardiology Foundation
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mhe prevalence of atrial septal aneurysm (ASA) in the
eneral population ranges from 1% in autopsy (1) to 2.2% in
ransesophageal echocardiographic (TEE) series (2,3).
trial septal aneurysm is rarely an isolated abnormality, but
t is frequently (50% to 89%) associated with a patent
oramen ovale (PFO) (1,2). Atrial septal aneurysm has been
ssociated with cerebral ischemia (2,4), and patients with
oth ASA and PFO constitute a high-risk population with
three- to five-fold increased risk for recurrent events
ompared to patients with PFO alone (5). Although trans-
atheter closure of PFO alone (6–8) has been shown to be
easible, treatment of patients with ASA  PFO has not
een systematically studied. We therefore investigated the
afety and efficacy of transcatheter treatment of ASA 
FO in a cohort of consecutive patients with presumed
aradoxical embolism and compared it to that of patients
ith PFO alone.
From the Departments of *Cardiology and †Neurology, University Hospital, Bern,
witzerland; and ‡Cardiovascular Center, Frankfurt, Germany.T
Manuscript received June 28, 2004; revised manuscript received October 17, 2004,
ccepted October 18, 2004.ETHODS
atient population. One hundred forty-one consecutive
atients with ASA  PFO and one or more documented
schemic stroke, transient ischemic attack (TIA), or periph-
ral embolism related to paradoxical embolism were re-
ruited from two institutions: University Hospital, Bern,
witzerland, and Cardiovascular Center, Frankfurt,
ermany. The control group consisted of 220 consecutive
atients with PFO alone undergoing percutaneous PFO
losure during the same period at the University Hospital,
ern, Switzerland. The study protocol was approved by the
ocal Ethics Committees, and patients gave written in-
ormed consent. An embolic event was considered due to
aradoxical embolism when the following criteria were
ulfilled: 1) presence of PFO with or without ASA with
pontaneous or inducible interatrial right-to-left shunt dur-
ng contrast TEE, 2) clinically and/or radiologically con-
rmed ischemic stroke, TIA, or peripheral embolism, and
) exclusion of any other identifiable cardiac, aortic, or
erebrovascular cause.
chocardiography. At baseline before closure and six
onths after transcatheter treatment, a paired-contrast
EE study was performed. The diagnosis of ASA was made
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Atrial Septal Aneurysm and PFO Feburary 1, 2005:377–80f: 1) the diameter of the base of the aneurysm measured
15 mm, and 2) the excursion of the aneurysmal membrane
xceeded 10 mm (3). Spontaneous or provoked right-to-
eft shunt was graded according to the amount of bubbles
rossing the interatrial septum: grade 0  none, grade 1 
inimal (1 to 5 bubbles), grade 2  moderate (6 to 20
ubbles), and grade 3  severe (20 bubbles) (6).
ollow-up evaluation. Outcome after the intervention was
rospectively assessed for up to six years. Two patients with
SA  PFO and five patients with PFO alone were lost to
ollow-up because of emigration. Patients underwent a
tructured telephone interview, addressing recurrent events,
evice problems, and health status at regular intervals.
ecurrent ischemic stroke, TIA, or peripheral embolism
ere considered end points. Patients with suspected recur-
ent events were re-examined by a neurologist, and an
maging study of the brain was repeated.
tatistical analysis. Continuous variables are expressed as
ean  1 SD and were compared by a two-sided t test.
ategorical variables are reported as counts and percentages,
nd were compared by chi-square analysis. Estimates for
reedom from recurrent TIA, stroke, and the composite of
IA, stroke, or peripheral embolism were obtained using
he Kaplan-Meier method. The log-rank test was used for
nivariate analysis of independent predictors of recurrence.
azard ratios (HRs) and 95% confidence intervals (CIs) for
ach independent variable were obtained by proportional
azard regression analysis. Statistical significance was as-
umed with a p value 0.05.
ESULTS
rocedural outcome. Demographic data are summarized
n Tables 1 and 2. A total of seven different atrial septal
Abbreviations and Acronyms
ASA atrial septal aneurysm
CI  confidence interval
HR  hazard ratio
PFO patent foramen ovale
TEE transesophageal echocardiography
TIA  transient ischemic attack
able 1. Demographics
ASA  PFO PFO Alone p
atients (n) 141 220
ge (yrs) 49  13 50  13 0.73
ale gender 75 (53%) 119 (54%) 0.86
ollow-up (yrs) 2.5  1.6 2.3  1.8 0.25
ndex event 0.43
Ischemic stroke 83 (59%) 138 (63%)
Transient ischemic attack 48 (34%) 73 (33%)
Peripheral embolism 10 (7%) 9 (4%)
rior embolic events
Mean number of events 1.7  1.04 1.7  1.07 0.89
More than one event 55 (39%) 83 (38%) 0.81oSA  atrial septal aneurysm; PFO  patent foramen ovale.cclusion devices were utilized depending on institutional
reference and device availability (Table 3). Device success
as 99.3% in patients with ASA  PFO and 99.5% in
atients with PFO alone (p  0.75). Procedural complica-
ions occurred with similar frequency in patients with ASA
PFO (one device embolization: 0.7%) and patients with
FO alone (four device embolizations, one cardiac tampon-
de, and two vascular access site complications: 3.2%; p 
.12).
chocardiographic findings. The effect of transcatheter
reatment of ASA  PFO on atrial septal mobility and
ight-to-left shunt is summarized in Figure 1 and Table 2.
aximal atrial septal excursion of ASA decreased from 16
5 mm before to 4  3 mm after the intervention (p 
.0001). A right-to-left shunt via the associated PFO was
bolished in 120 (86%) patients, whereas a minimal, mod-
rate, or large residual shunt persisted in 11 (8%), 6 (4%),
nd 3 (2%) patients, respectively. In patients with PFO
lone, complete closure was achieved in 187 (85%) patients,
hereas a minimal, moderate, or large residual shunt per-
isted in 19 (9%), 6 (3%), and 7 (3%) patients, respectively
p  0.80 for the comparison with patients with ASA 
FO). Device size categorized as small (30 mm; n  83
atients) or large (30 mm; n 58 patients) had no impact
n the incidence of procedural complications (small 1.2% vs.
arge 0%; p  0.40) and residual shunt rate (small 15% vs.
arge 14%; p  0.89) in patients with ASA  PFO.
linical outcome. During follow-up, there were no differ-
nces with respect to recurrent TIA, stroke, and the
omposite of recurrent TIA, stroke, or peripheral embolism
etween patients with ASA  PFO and those with PFO
lone (Table 4). Freedom from the composite end point of
ecurrent TIA, stroke, or peripheral embolism at four years
as 95% and 94%, respectively (p  0.70) (Fig. 2). The
resence of a residual right-to-left shunt after transcatheter
reatment of ASA  PFO was the only predictor for
ecurrent events (HR 6.9; 95% CI 1.3 to 36.9, p  0.03)
Fig. 3).
ISCUSSION
revious reports (6–8) have shown transcatheter treatment
able 2. Right-to-Left Shunt as Assessed by Contrast
ransesophageal Echocardiography
ASA  PFO PFO Alone p
hunt at baseline 0.18
Grade I 2 (1%) 7 (3%)
Grade II 21 (15%) 46 (21%)
Grade III 118 (84%) 167 (76%)
hunt six months after
transcatheter treatment
0.80
No shunt 120 (86%) 187 (85%)
Grade I 11 (8%) 19 (9%)
Grade II 6 (4%) 6 (3%)
Grade III 3 (2%) 7 (3%)
bbreviations as in Table 1.f patients with cryptogenic stroke and PFO alone to be
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Feburary 1, 2005:377–80 Atrial Septal Aneurysm and PFOeasible using a variety of trans-septal occlusion devices.
lthough most series included only a few patients with an
ssociated ASA, the present study is the first series to
nvestigate the safety and long-term efficacy of transcatheter
reatment of ASA  PFO in a sizeable cohort of patients.
he principal findings of the study are: 1) transcatheter
reatment of ASA  PFO is safe; 2) procedural success and
omplications of transcatheter treatment of ASA  PFO
re similar to the treatment of patients with PFO alone; 3)
he additional presence of ASA does not adversely affect
limination of right-to-left shunt compared with PFO
lone; and 4) the long-term risk of recurrent events after
ranscatheter treatment of ASA  PFO is comparable to
hat of patients with PFO alone.
Patients with ASA  PFO are at higher risk for stroke
nd stroke recurrence compared to patients with PFO alone,
nd secondary prevention with acetylsalicylic acid appears
nsufficient to protect against recurrence (4). Atrial septal
able 3. Implanted Devices
Device Type
Patients
(n)
Pro
Comp
SA  PFO
Sideris buttoned device 8
Angel-wings occluder 5
Amplatzer atrial septal occluder 4
CardioSEAL/STARFlex septal occluder 13
PFO-STAR septal occluder 36
Amplatzer PFO occluder 56
Helex septal occluder 19
Totals 141 1 (
FO alone
Sideris buttoned device 24
Angel-wings occluder 8
Amplatzer atrial septal occluder 5
CardioSEAL/STARFlex septal occluder 5
PFO-STAR septal occluder 46
Amplatzer PFO occluder 131
Helex septal occluder 1
Totals 220 7 (
bbreviations as in Table 1.
igure 1. Effect of transcatheter treatment of atrial septal aneurysm and
p

atent foramen ovale on atrial septal mobility as assessed by paired
ransesophageal echocardiography.neurysm may act as facilitator for paradoxical embolism via
he following mechanisms: 1) it may increase the PFO
iameter due to the highly mobile atrial septal tissue,
eading to a more frequent and wider opening of an
therwise small channel (9,10); 2) atrial septal aneurysm
ay promote right-to-left shunting by redirecting flow from
he inferior vena cava toward the PFO (11); and 3) atrial
eptal aneurysm has been considered a nidus for local
hrombus formation with subsequent embolization (1).
The results of the present study indicate that the right-
o-left shunt as principal mechanism of ASA-related em-
olism can be effectively eliminated in the majority of
atients. Transcatheter treatment of ASA  PFO also
educes atrial septal mobility. This effect most likely results
rom immobilization of redundant atrial septal tissue be-
ween the device discs. Initially, it was surmised that this
igure 2. Freedom from the composite of recurrent transient ischemic
ttack, stroke, or peripheral embolism after transcatheter treatment for
al
ions
Residual
Shunt
Recurrent
Embolism
Cumulative Follow-Up
(Patient-Yrs)
4 (50%) 0 52
1 (20%) 1 22
1 (25%) 1 10
2 (15%) 0 46
6 (17%) 3 93
5 (9%) 1 91
1 (5%) 0 32
) 20 (14%) 6 346
10 (42%) 2 123
1 (13%) 1 35
2 (40%) 0 26
0 0 19
8 (17%) 6 109
11 (8%) 1 181
0 0 1
) 32 (15%) 10 494cedur
licat
0
0
1
0
0
0
0
0.7%
4
0
0
0
3
0
0
3.2%atients with atrial septal aneurysm and patent foramen ovale (ASA
PFO) and patients with PFO alone.
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Atrial Septal Aneurysm and PFO Feburary 1, 2005:377–80ight decrease the potential for local thrombus formation.
owever, the current data refute this and corroborate that
he PFO is instrumental, whereas the ASA acts as facilitator
nly. The present study also suggests that there may be no
eed to oversize devices in an attempt to stent the floppy
eptum. This observation could allow for the implantation
f smaller devices more snuggly nested in the fossa ovalis,
nd thus more likely to afford complete closure of the PFO.
tudy limitations. The following limitations should be
onsidered in the interpretation of our results. 1) The
iagnosis of paradoxical embolism remains presumptive,
nd cryptogenic embolism is not necessarily synonymous
ith paradoxical embolism. 2) The dimensional definitions
f ASA vary, with excursions ranging from 6 to 15 mm. The
neurysmal excursion exceeded 10 mm in all patients in our
tudy, and therefore, the results should apply to the majority
f patients with ASA  PFO. 3) Comparison of patients
ith ASA  PFO from two centers with a control group
rom only one center increases the possibility of bias or
onfounders despite similar patient characteristics. 4) Pa-
ients with PFO alone have been included in the present
igure 3. Predictors for the composite of recurrent transient ischemic
ttack, stroke, or peripheral embolism after transcatheter treatment of atrial
eptal aneurysm and patent foramen ovale. CI  confidence interval; HR
able 4. Recurrent Events
Events
ASA  PFO PFO Alon
atients (n) 141 220
ecurrent TIA, stroke, or peripheral
embolism
6 10
ecurrent stroke 1 4
ecurrent TIA 5 4
Probabilities of events were derived from Kaplan-Meier analyses. †Hazard ratios (HR
ere calculated with the log-rank test.
TIA  transient ischemic attack; other abbreviations as in Table 1.hazard ratio.tudy as a reference group to provide a comparison with
espect to procedural, echocardiographic, and clinical out-
ome. However, this comparison is not randomized, and
otential differences between patient groups beyond the
nteratrial septal abnormality cannot be excluded and may
ave affected the outcome.
eprint requests and correspondence: Dr. Stephan Windecker,
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